Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Refractory or Relapsed Solid Tumors 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Rifampin × 90 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡